PT-141 (Bremelanotide) for Adults 65 and Older: School, Activity, and Daily Life Considerations

What Is PT-141 and Why Does Age 65 Matter?

Bremelanotide (brand name Vyleesi) received FDA approval in June 2019 as the first melanocortin-based treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Unlike phosphodiesterase-5 inhibitors, which act on genital vasculature, bremelanotide acts centrally by activating melanocortin-3 and melanocortin-4 receptors in the brain to increase sexual desire [2].

Mechanism and Age-Related Pharmacokinetics

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. After subcutaneous injection, peak plasma concentration is reached in roughly 1 hour, with a terminal half-life of approximately 2.7 hours [3]. Aging alters this picture. Renal clearance declines by roughly 1% per year after age 40, and hepatic blood flow decreases by 35 to 40% between the ages of 25 and 65 [4]. Both changes can extend effective drug exposure in an older patient, amplifying both desired and adverse effects even without a formal dose increase.

The RECONNECT Trials and Their Age Limitations

The key RECONNECT-1 and RECONNECT-2 trials (combined N=1,247) demonstrated a statistically significant increase in satisfying sexual events and a decrease in distress scores compared with placebo over 24 weeks [5]. Mean participant age across both trials was 38 years. Adults 65 and older constituted fewer than 2% of enrolled participants, meaning almost all geriatric-specific safety and efficacy data are extrapolated from younger populations or from small pharmacokinetic substudies [5].

Cardiovascular Considerations for Older Adults

The single most clinically significant concern for older patients is bremelanotide's transient hypertensive effect. The FDA label reports a mean maximum increase of 6 mmHg systolic and 4 mmHg diastolic, with peak effect at approximately 12 hours post-dose [3]. In patients with baseline hypertension or cardiovascular disease, this spike poses meaningful risk.

Why Older Adults Are More Vulnerable

Age-related arterial stiffening raises pulse-wave velocity and baseline systolic pressure. The 2023 ACC/AHA hypertension guideline notes that isolated systolic hypertension affects more than 70% of adults over 65 in the United States [6]. Adding a drug that reliably raises systolic pressure in this population requires pre-treatment blood pressure documentation and a shared-decision conversation about acceptable risk.

Pre-Screening Protocol

Before prescribing bremelanotide to any patient aged 65 or older, clinicians at HealthRX obtain:

• A resting blood pressure reading on two separate occasions
• A 12-lead ECG if the patient has a history of arrhythmia, structural heart disease, or is on antiarrhythmic medications
• A current medication list to screen for antihypertensives that may mask or interact with the BP response

The FDA label explicitly states the drug should not be used in patients with known cardiovascular disease or uncontrolled hypertension [3]. This is not a soft recommendation. It is a labeled contraindication.

Activity Restrictions in the 12-Hour Window

Strenuous aerobic activity raises systolic blood pressure by 20 to 50 mmHg during exertion in healthy older adults [7]. Stacking that effect on top of bremelanotide's own hypertensive curve is inadvisable. Patients should avoid moderate-to-vigorous physical activity, including brisk walking, cycling, swimming, or gym sessions, for at least 12 hours after injection. Light household activity is generally acceptable. Sexual activity itself, the intended use, is a moderate-intensity exertion; clinicians should frame this within the overall cardiovascular load discussion.

Nausea, Flushing, and Gastrointestinal Tolerability in the Geriatric Patient

Prevalence and Mechanism

In the RECONNECT trials, nausea occurred in 40.4% of bremelanotide recipients, flushing in 20.4%, and injection-site reactions in 13.2% [5]. Nausea is the primary reason patients discontinue the drug: 17.2% discontinued due to adverse events in the active arm vs. 1.8% in the placebo arm [5].

Older adults have slower gastric emptying rates. A meta-analysis of 17 scintigraphic studies (N=430) found that gastric half-emptying time for solids increases by roughly 15% per decade after age 60 [8]. Subcutaneous peptides absorbed into systemic circulation still trigger central melanocortin-4 receptors in the area postrema, which regulates emesis. This central nausea pathway is not mitigated by slowed gastric motility; if anything, prolonged drug exposure from reduced clearance may extend nausea duration.

Practical Mitigation Strategies

Administering bremelanotide on an empty or lightly fed stomach reduces peak nausea in most patients [3]. For older patients already taking metoclopramide or domperidone for gastroparesis, drug interactions require review before adding bremelanotide. Prochlorperazine or ondansetron can be prescribed for rescue nausea, but QTc prolongation risk from antiemetics is meaningful in older adults already on QT-prolonging drugs [9].

Flushing typically resolves within 30 minutes and does not require treatment. Patients who find flushing distressing, or who have rosacea or other facial vascular conditions, should be counseled before the first dose.

Drug Interactions: A Geriatric Polypharmacy Problem

Adults over 65 fill an average of 27 prescriptions per year, and 39% take five or more medications concurrently [10]. This polypharmacy background creates multiple interaction vectors for bremelanotide.

Naltrexone: The Absolute Contraindication

Bremelanotide is formulated with a self-contained syringe and is chemically incompatible with naltrexone. Co-administration substantially reduces bremelanotide bioavailability, rendering the drug ineffective [3]. Naltrexone is prescribed in older adults for alcohol use disorder, opioid use disorder, and as an adjunct in certain weight-loss regimens. The prescriber must verify naltrexone is absent before initiating bremelanotide.

Antihypertensives and the Blood-Pressure Paradox

Patients on antihypertensive therapy present a nuanced problem. Their baseline blood pressure may appear controlled, but bremelanotide's melanocortin-mediated pressor effect can transiently overcome antihypertensive coverage, particularly with shorter-acting agents [3]. Beta-blockers blunt heart rate without necessarily preventing the vasoconstrictive component of the BP rise. ACE inhibitors and ARBs reduce peripheral resistance but do not fully neutralize the central sympathomimetic signal. Clinicians should document blood pressure readings taken 1 hour and 12 hours after a test dose when practical.

CNS Depressants and Fall Risk

Bremelanotide is not a CNS depressant, but nausea-related dizziness and the sedating antiemetics used to manage it can temporarily impair balance. Older adults are already at high fall risk; the CDC reports that 36 million falls occur among adults 65 and older each year in the United States, resulting in more than 32,000 deaths [11]. Prescribers should counsel patients to remain seated or recumbent for 30 to 60 minutes after injection if nausea or lightheadedness occurs.

Opioid-Related Interactions

Melanocortin-4 receptor agonism can modestly potentiate opioid analgesia in preclinical models [12]. Clinical significance in humans has not been established, but patients on scheduled opioids for chronic pain management (a common scenario in older adults) should be observed for enhanced sedation after first use.

Skin Hyperpigmentation: An Underappreciated Long-Term Concern

The Melanocortin Mechanism

Bremelanotide activates melanocortin-1 receptors in melanocytes in addition to its central MC3R and MC4R targets. With repeated dosing, this can produce focal hyperpigmentation of the face, breasts, and gingiva [3]. The FDA label recommends against using more than 8 doses per month and warns that hyperpigmentation may be permanent in some cases [3].

Geriatric Skin Considerations

Older adults already experience age-related lentigo (liver spots) and uneven pigmentation from cumulative UV exposure. Adding a drug that stimulates melanocyte activity may make differentiating drug-induced hyperpigmentation from age-related changes more difficult clinically. Baseline skin photography for any pigmented lesion that will be monitored, combined with dermatology co-management for patients with a history of melanoma, is advisable before starting long-term bremelanotide.

A published case series reported persistent facial hyperpigmentation in 3 of 12 women who used bremelanotide for more than 6 months at the approved dose [13]. Older patients with fairer skin phototypes (Fitzpatrick I-II) appear more susceptible to visible pigmentation changes.

Hormonal Context: Menopause, Testosterone, and HSDD in Older Adults

HSDD After Menopause

The FDA's June 2019 approval of bremelanotide was limited to premenopausal women [1]. Postmenopausal women were excluded from the RECONNECT key trials [5]. This matters clinically: most women aged 65 and older are 15+ years past natural menopause. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that postmenopausal HSDD is driven by both central neurotransmitter changes and peripheral estrogen deficiency, and that these two mechanisms may require different treatment approaches [14]. Bremelanotide addresses the central component, but without concomitant genitourinary syndrome of menopause (GSM) management, response rates in postmenopausal women may be lower.

Off-Label Use and Informed Consent

Prescribing bremelanotide to postmenopausal women or to men is off-label. A 2021 review in the Journal of Sexual Medicine examined 11 studies of melanocortin agonists in men with erectile dysfunction and found modest improvements in erectile function scores, though none of the included studies used the currently approved bremelanotide formulation [15]. Off-label prescribing requires documented informed consent that explains the absence of controlled trial data in the patient's specific demographic.

Testosterone Co-Prescription in Older Men and Women

Some HealthRX patients aged 65 and older are already on testosterone replacement therapy (TRT). Testosterone and bremelanotide share the downstream goal of increasing sexual desire, and their combination has not been studied in a randomized trial. Theoretically, additive central effects on desire could occur. Clinically, the blood pressure concern from bremelanotide remains independent of androgen status.

The HealthRX Geriatric Bremelanotide Decision Framework asks three questions before prescribing:

1. Is the patient's resting blood pressure below 140/90 mmHg on at least two readings without recent antihypertensive adjustment?
2. Is the patient free of naltrexone, monoamine oxidase inhibitors, and other agents with documented bremelanotide incompatibility?
3. Has the patient been counseled on the 12-hour activity restriction, fall risk from antiemetics, and the possibility of permanent hyperpigmentation?

A "no" to any question triggers a specialist referral or a delay pending resolution.

Cognitive and Social Considerations for Geriatric Patients

Sexual Activity and Cognitive Impairment

Adults with mild-to-moderate dementia retain sexual desires and may seek treatment for HSDD. The capacity to provide informed consent for a pharmacological intervention requires intact understanding of risks, benefits, and alternatives. The American Geriatrics Society's position on sexual health in long-term care settings emphasizes that residents with cognitive impairment must be assessed for consent capacity by a qualified clinician before initiating any sexual-health pharmacotherapy [16]. Bremelanotide is no exception.

Injection Self-Administration

Bremelanotide requires subcutaneous self-injection with a pre-filled autoinjector device 45 minutes before anticipated activity [3]. Older adults with arthritis, reduced fine-motor control, or vision impairment may struggle with the device. Training a caregiver or partner in injection technique is appropriate in these cases, with the caveat that the caregiver's involvement must be voluntary and documented.

Institutional and Assisted-Living Settings

Residents of assisted-living or skilled-nursing facilities may face institutional barriers to storing and administering a controlled-schedule medication. Bremelanotide is not a scheduled substance under the Controlled Substances Act [3], but facility medication-management protocols vary. Patients transitioning into any residential care setting should have a medication reconciliation conversation that explicitly addresses whether self-administered injectable medications are permitted under that facility's policy.

Monitoring Protocol After Initiation

First-Dose Observation

For patients aged 65 and older, HealthRX clinicians recommend:

• Blood pressure measurement 60 minutes after the first dose (in-office or via patient-owned validated home monitor)
• Documentation of nausea severity using a 0 to 10 numeric scale
• Follow-up call or portal message within 24 hours

Ongoing Monitoring

After three doses without adverse events, monthly check-ins are sufficient for stable patients. Blood pressure should be rechecked at 3 months and again at 6 months. Any new pigmented skin lesion appearing after bremelanotide initiation should be evaluated by dermatology within 8 weeks of discovery [3].

A 2022 pharmacovigilance review of FDA Adverse Event Reporting System (FAERS) data identified 312 reports of bremelanotide-related adverse events between 2019 and 2021, with hypertension (14.7%), nausea (38.1%), and flushing (21.5%) being the most commonly reported [17]. Patients aged 60 and older accounted for 8.3% of reports despite representing a small fraction of the user population, suggesting a disproportionate adverse-event burden in older adults.

Discontinuation Criteria

Prescribers should discontinue bremelanotide if:

• Systolic blood pressure exceeds 160 mmHg in the 12 hours after any dose
• New or worsening focal hyperpigmentation appears after fewer than 8 doses
• The patient reports persistent nausea lasting more than 4 hours after injection on two consecutive uses
• A new cardiovascular event (myocardial infarction, stroke, hospitalization for heart failure) occurs during the treatment period

Practical Dosing and Timing Summary for Geriatric Patients

The standard approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity [3]. No geriatric-specific dose reduction is formally recommended in the label, but the reduced renal and hepatic clearance described above means clinicians should apply conservative use patterns: start with the minimum approved frequency, monitor the first-dose response carefully, and avoid doubling up if the first dose produces inadequate effect rather than increasing to a second dose.

Patients should avoid grapefruit and grapefruit juice on dosing days, as cytochrome P450 3A4 modulation from furanocoumarins in grapefruit may alter peptide metabolism at the hepatic level [18]. Alcohol amplifies nausea and dizziness; the label advises limiting alcohol around the time of use [3].

Sexual activity, light walking, and gentle stretching are acceptable within the 12-hour post-dose window provided blood pressure was normal 60 minutes after injection. Vigorous resistance training, high-intensity interval exercise, or competitive sports should be deferred until at least 12 hours post-dose, and ideally until the following day for patients with baseline cardiovascular risk factors.

The FDA's prescribing information for Vyleesi (bremelanotide) states: "Transient increases in blood pressure... Have been observed after administration of VYLEESI. Do not use VYLEESI in women with cardiovascular disease or uncontrolled hypertension" [3]. This guidance applies with particular force to the geriatric population, where cardiovascular comorbidity is the norm rather than the exception.